Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Advanced GIST
NCT00940563Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2002
- Primary completion
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Tumor Response (RECIST Criteria). Started Mar 2002; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00940563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940563.